Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott touts portfolio balance in downturn

This article was originally published in The Tan Sheet

Executive Summary

The Abbott Park, Ill.-based health firm expects to overcome a slight drop in first quarter revenue, from $6.8 billion to $6.7 billion, with a "well-balanced, highly diverse portfolio," CEO Miles White said during an April 15 earnings call. The company's global nutritionals business sold $1.2 billion in the January-March period, a 6.4 percent jump from the year-ago period, including the negative effects of foreign exchange. John Thomas, VP of investor relations, said Glucerna and Ensure drove a 6.2 percent increase in U.S. adult nutritional sales, to $288 million. U.S. pediatric nutritionals fell 3.2 percent to $295 million. Thomas added Abbott expects mid- to high-single digit domestic nutritionals growth in its second quarter, and flat sales overseas. Overall, net earnings reached $1.4 billion for the quarter, up 53.4 percent. The firm confirmed its earnings per share guidance of $3.65 to $3.70 for fiscal 2009
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS102815

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel